Arkin Holdings

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Werewolf Therapeutics operates as an oncology biotherapeutics company advancing a pipeline of transformative cancer treatments. Werewolf Therapeutics is developing medicines designed to be delivered systemically, but remain inactive in the body until they reach the tumor microenvironment, where they stimulate a powerful immune response and unleash an attack on cancer cells.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Percepto is a developer of autonomous drone technology for inspection and surveillance. Drones hold the potential to disrupt multi-billion dollar industries including energy, security, insurance, agriculture, and more. Drones completely change the way inspection, measurement, surveillance, and deliveries are done today. Still, the main barrier to making them a must-have platform is the ability of drones to perform tasks autonomously. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the most deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring) the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.

Pixellot LTD offers outdoor broadcast video capture and production devices for second tier sports events and practice games. The company also offers a virtual, compact, and automated production suite that can be located either at the venue or at a remote location. Pixellot LTD is based in Tel Aviv, Israel.

Metabomed LTD. discovers and develops potential small molecule drugs directed against targets in the field of cancer metabolism. The company identifies new targets that form a synthetic lethal gene pair with metabolic genes inactivated in cancer cells and by inhibiting these targets, the company develops selective anti-cancer drugs that may potentially be highly targeted, and therefore spare normal cells. The company was founded in 2013 and is based in Yavne, Israel.

MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists with notifications about their dosage activity, which can be monitored remotely through a patient profile's on MedMinder's website. The company was founded in 2007 and is headquartered in Needham, Massachusetts.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Virility is developing intimate and disposable skin patch. The patch carries an electronic module which generates neuromuscular electrical stimulation. The stimulation is delivered transcutaneously to the adjacent musculature, thus delaying the onset of the premature phase of ejaculation.

Digma Medical is a clinical stage medical device company revolutionizing the treatment of Type-2 Diabetes and other metabolic syndrome disease such as NASH. Founded in 2013 and backed by leading venture capital firms, Digma is dedicated to the development of the DiaGone™ to treat insulin resistance - the underlying mechanism of the disease. The DiaGone™ is an endoscopic, disposable device, that uses state of the art laser technology to treat the duodenum without an implant. The Duodenal Glycemic Control™ procedure is a one-time 30 minute GI procedure, in which the gastroenterologist uses the DiaGone™ to treat the duodenum for restoring the natural ability of the body to control glucose levels, which may provide long term remission from Type-2 Diabetes, NASH, and other metabolic syndrome related disease.

EDocate provides a platform for simulation-based learning in which medical professionals can learn to care for long-term diseases. The platform offers virtual patient simulations, gamification, mobile and client access, and interaction through social networks. It tailors it to the learning habits and busy lifestyle of adult learners, with a focus on practice skills and optimized quality of care.

Pi Therapeutics Ltd develops small molecule inhibitors for the treatment of tumor cancers. The company was founded in 2015 and is based in Ness Ziona, Israel.

Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.

Fu-Gen AG, an independent power producer and asset manager, engages in developing, constructing, and managing renewable energy projects in Sweden and Italy. The company is based in Zug, Switzerland.

Welcome Building Corporation engages in the designing, customization, and selling of residential properties. It provides contemporary home models and other home building services. The company was founded in 2020 and is based in New York, New York.

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.

cCAM Biotherapeutics Ltd., a clinical stage company, engages in the discovery and development of novel immunotherapies to treat cancer. It offers CM-24, a humanized anti CEACAM1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1 for the treatment of advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers. cCAM Biotherapeutics Ltd. was founded in 2010 and is based in Misgav, Israel. As of July 31, 2015, cCAM Biotherapeutics Ltd operates as a subsidiary of Merck & Co. Inc.

Vision Cortex Ltd. develops computer vision solutions to provide recognition, tracking, and odometry capabilities in drones and UAVs. Its solutions enable drones and UAVs to provide search and rescue, security and monitoring, gesture control, autonomous filming, surveillance, supervision, autonomous navigation, 3D mapping, and obstacle avoidance applications. The company was founded in 2014 and is based in Tel Aviv, Israel.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate of functional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.

HI-Bio was established on the premise that treatments for immune-mediated illnesses have the potential to provide patients with better outcomes. Many IMDs are caused by immune system cells, such as mast cells, neutrophils, plasma cells, and more, which are dysfunctional. These cells are in charge of crucial processes and functions. With the use of medicines, HI-efforts Bio uses a precision medicine strategy to target, modify or deplete key cellular disease drivers. HI-Bio was established in 2021 in San Francisco, California.

Eleos Health is a developer of a SaaS based tool that track mental health.

Revamp medical was founded in 2016 with the goal of resolving one of the most urgent unmet needs in Acute Heart Failure patients. Targeting a market of >1M annual admissions in the US with a direct cost of $65B, Revamp is set to deliver an easily adoptable solution using its patented temporary catheter, Doraya™. Revamp has a seasoned team of professionals with a proven track record in leading multiple med-tech startups.

Pigmentum is an ag-tech firm developing a molecular technology platform that enables external gene activation in plants.

Nest Genomics is a lab-agnostic, comprehensive software solution for implementing genomic programs at scale.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Lendbuzz Funding, LLC offers car loans to expats and international students. The company does not require Social Security Number (SSN) and provides loans to all visa holders from all nationalities. Its customers include students, international professionals, and other young professionals that have an international credit file. The company provides access and manages its loans through an online platform and data-intensive scoring technology. Lendbuzz Funding, LLC was founded in 2015 and is based in Boston, Massachusetts.

Quiet Therapeutics is an emerging biotech company founded in 2010 developing a proprietary nanoparticle-based delivery system (gagomers) focused on oncology and inflammation. Based on the targeting capability of our innovative technology, the company is well positioned to expand the drug target repertoire in cancer and inflammation. The Gagomer delivery approach enables us to target cell components that are not manageable by other therapeutic agents like small molecules or antibodies.

BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy ​​treatments.​​​

BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy ​​treatments.​​​

Eleos Health is a developer of a SaaS based tool that track mental health.

Mindspace is a boutique flex space provider, presenting a global mindset with a local flavor. We redefine the workplace experience for companies of all sizes. Our beautifully designed spaces, personalized level of service and carefully curated events foster enhanced employee engagement and a strong sense of community, accommodating the way people work, innovate and grow. Our customer base includes blue-chip companies, enterprises and SMBs, in 31 locations, 16 cities and 7 countries across Europe and the US.

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.

Werewolf Therapeutics operates as an oncology biotherapeutics company advancing a pipeline of transformative cancer treatments. Werewolf Therapeutics is developing medicines designed to be delivered systemically, but remain inactive in the body until they reach the tumor microenvironment, where they stimulate a powerful immune response and unleash an attack on cancer cells.

Eleos Health is a developer of a SaaS based tool that track mental health.

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.

BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy ​​treatments.​​​

Eleos Health is a developer of a SaaS based tool that track mental health.

Phytolon is a food and beverage company that offers a technology designed for the production of natural food colorants using bakers yeast cells as bio-factory. It specializes in fermentation to create a natural food colorant.

EDocate provides a platform for simulation-based learning in which medical professionals can learn to care for long-term diseases. The platform offers virtual patient simulations, gamification, mobile and client access, and interaction through social networks. It tailors it to the learning habits and busy lifestyle of adult learners, with a focus on practice skills and optimized quality of care.

Vision Cortex Ltd. develops computer vision solutions to provide recognition, tracking, and odometry capabilities in drones and UAVs. Its solutions enable drones and UAVs to provide search and rescue, security and monitoring, gesture control, autonomous filming, surveillance, supervision, autonomous navigation, 3D mapping, and obstacle avoidance applications. The company was founded in 2014 and is based in Tel Aviv, Israel.

Laguna Health is a digital health insurance company that helps people realize their recovery potential. It was founded by Yoni Shtein and Yael Peled Adam in 2020 in Tel Aviv, Tel Aviv, Israel.

Lendbuzz Funding, LLC offers car loans to expats and international students. The company does not require Social Security Number (SSN) and provides loans to all visa holders from all nationalities. Its customers include students, international professionals, and other young professionals that have an international credit file. The company provides access and manages its loans through an online platform and data-intensive scoring technology. Lendbuzz Funding, LLC was founded in 2015 and is based in Boston, Massachusetts.

Fu-Gen is an entrepreneurial independent power producer and renewable energy investor.

BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy ​​treatments.​​​

BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy ​​treatments.​​​

ARTSaVIT is a biopharmaceuticals company developing a cancer drug.

Redpin Therapeutics, Inc., gene therapy company, develops a chemo genetics platform for targeted cell therapies that address intractable diseases of the nervous system. It discovers and develops an ion channel-based chemo genetics platform that enables targeted cell activation/inhibition controlled by low doses of the anti-smoking drug Varenicline. Redpin Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.

Sol-Gel designs and delivers innovative dermatological drugs ranging from completely non-leachable to highly-controlled-release of unique formulations and compounds.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Honeycomb (fka Agilius) is the only place where you can buy a condo/apartment building master policy online in less than 3 minutes at a fraction of the cost! Instant, free, no hassle quotes, online everything and up to 40% savings. With all that we're bringing simplicity and transparency to the real estate insurance space for condo associations (HOAs), building owners, property managers, and developers everywhere. This is what we do. This is all we do.

MadeRight offers a natural additive that enhances sustainable packaging. A natural additive fermented by fungi grown on industrial waste, serving as a performance enhancer for bio-plastics. It enables a scalable, affordable, and degradable additive to any plastic mix, improving the physical attributes and functional performance of the produced packaging material, including anti-microbial and heat resistance.

Eleos Health is a developer of a SaaS based tool that track mental health.

Percepto is a developer of autonomous drone technology for inspection and surveillance. Drones hold the potential to disrupt multi-billion dollar industries including energy, security, insurance, agriculture, and more. Drones completely change the way inspection, measurement, surveillance, and deliveries are done today. Still, the main barrier to making them a must-have platform is the ability of drones to perform tasks autonomously. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the most deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring) the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.

Welcome Building Corporation engages in the designing, customization, and selling of residential properties. It provides contemporary home models and other home building services. The company was founded in 2020 and is based in New York, New York.

Validic is the healthcare industry's premier technology platform for convenient, easy data access to a world of mobile health and in-home devices, fitness equipment, clinical sensors, activity wearables, smart bands, and wellness applications. Founded in 2010, Validic is headquartered in Durham, North Carolina.

Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein post-translational modifications, going beyond degradation to restore protein function, repair signaling, and amplify endogenous disease-fighting mechanisms. Photys was co-founded by the Broad Institute’s leading bifunctional chemist, Amit Choudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers – MIT’s Angela Koehler, Salk’s Tony Hunter, Berkeley’s Dan Nomura, MPM’s Wendy Young, and Dana Farber’s Eric Fischer.

Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate of functional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.

MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists with notifications about their dosage activity, which can be monitored remotely through a patient profile's on MedMinder's website. The company was founded in 2007 and is headquartered in Needham, Massachusetts.

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.